Interventional radiology

ProKidney Reports First Quarter Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, May 11, 2023
Injection, Society, Kidney failure, Chronic kidney disease, Diabetes, Society of Interventional Radiology, Clinical trial, REACT, SIR, Dialysis, Interventional radiology, Patient, Kidney, Research, CKD, Safety, Biopsy, D, Pharmaceutical industry, Cryptocurrency, EU

WINSTON-SALEM, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments.

Key Points: 
  • WINSTON-SALEM, N.C., May 11, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the first quarter ended March 31, 2023, and provided an update on recent corporate developments.
  • “Patient enrollment in proact 1 continues according to plan and we target interim data by year end 2024.
  • With enrollment complete, we continue to biopsy, treat, and monitor patients following administration of REACT, evaluating them as they progress through the 18-month follow up period.
  • Liquidity: Cash, cash equivalents and marketable securities as of March 31, 2023, totaled $463.7 million, compared to $490.3 million on December 31, 2022.

La Jolla Vein & Vascular Celebrates Opening of New Clinic in North County San Diego

Retrieved on: 
Thursday, May 11, 2023
Managed Care, Radiology, Health, Surgery, Lymphedema, Osteoarthritis, Interventional radiology, Rancho Santa Fe, California, Amputation, Varicose veins, PAD, Ageing, Multimedia, Municipal council, Varicocele, Moyamoya disease, De Young, Arusha City Council, Patient, Physician, Swelling, Uterine fibroid, Deep vein thrombosis, Diagnosis, GAE, May–Thurner syndrome, Commerce, Pelvic congestion syndrome, Medical imaging

La Jolla Vein & Vascular held a ribbon cutting and open house this week to celebrate the newly opened Vein Clinic and Endovascular Center.

Key Points: 
  • La Jolla Vein & Vascular held a ribbon cutting and open house this week to celebrate the newly opened Vein Clinic and Endovascular Center.
  • View the full release here: https://www.businesswire.com/news/home/20230511005703/en/
    Dr. Nisha Bunke (with scissors) kicks off the ribbon cutting ceremony to celebrate the opening of La Jolla Vein & Vascular's new medical clinic in Vista, California on May 9th, 2023.
  • “This new clinic was created to offer greater support for patients who need specialized vascular care,” said Dr. Nisha Bunke, Medical Director of La Jolla Vein & Vascular.
  • “Our first office in La Jolla was established in 2010, where many of our patients drive long distances to receive care.

Mercurius Health equips Robert Janker Klinik with integrated oncology solutions from Philips and Elekta

Retrieved on: 
Wednesday, May 10, 2023
Informatics, Partnership, Clinic, B2B, Neoplasm, Pathology, Cancer, Diagnosis, Prostate, Genomics, Radiology, Interventional radiology, Radiation, Acquisition, Patient, Risk, Palliative care, AEX, Mercury (mythology), PHG, Oncology, Health, EKTA, NYSE, Medical imaging, Elekta, Radiation therapy

The investment in Philips and Elekta solutions by Mercurius Health is part of its commitment to establishing a major presence in Germany, following the company’s acquisition of Robert Janker Klinik earlier this year.

Key Points: 
  • The investment in Philips and Elekta solutions by Mercurius Health is part of its commitment to establishing a major presence in Germany, following the company’s acquisition of Robert Janker Klinik earlier this year.
  • The agreement has been enabled by the strategic partnership between Philips and Elekta to advance comprehensive personalized cancer care through the deployment of precision oncology solutions.
  • The Robert Janker Klinik, a specialized hospital in oncology and palliative care, focuses on minimally invasive diagnostics and treatments for cancer.
  • Philips and Elekta bring all this data together and translate it into actionable insights, and pathways with predictable outcomes for each patient [1].

National Surgical Centers Stockton Adds FDA-Approved Procedure to Relieve Painful Diabetic Neuropathy

Retrieved on: 
Tuesday, May 9, 2023
Hypersensitivity, Injection, Diabetic neuropathy, PDN, Interventional radiology, Diabetes, Stabbing, Spinal cord, Medicine, Brain, Sensation, Pain, Food and Drug Administration, La Senza, MD, HFX, Freezing, Patient, FDA, Chronic pain, Paresthesia, Food, Safety, Conditional sentence, SCS, Dentistry, Pharmaceutical industry, Medical device

STOCKTON, Calif., May 9, 2023 /PRNewswire/ -- National Surgical Centers Stockton (NSC Stockton), an outpatient surgery center, is now offering high-frequency spinal cord stimulation (SCS) procedure(s) for the treatment of painful diabetic neuropathy (PDN). The technology, called HFX, is made by medical device company NEVRO of Redwood City, Calif. HFX is an FDA-approved, non-drug treatment for PDN and is the only paresthesia-free therapy approved by the FDA to treat painful diabetic neuropathy (PDN) with unrivaled evidence-based outcomes.

Key Points: 
  • Painful diabetic neuropathy causes pain in the limbs, often managed by medicine that is inadequate for long-term relief
    STOCKTON, Calif., May 9, 2023 /PRNewswire/ -- National Surgical Centers Stockton (NSC Stockton), an outpatient surgery center, is now offering high-frequency spinal cord stimulation (SCS) procedure(s) for the treatment of painful diabetic neuropathy (PDN).
  • "People with painful diabetic neuropathy know it to be a cruel addition to the chronic disease they must fight every day," said B.J.
  • Sandhu, MD, Interventional Radiologist at National Surgical Centers Stockton.
  • In a recent study, 92% of patients reported high satisfaction with the therapy.4
    For important safety information regarding this treatment, please visit www.HFXforPDN.com .

EQS-News: MediClin AG: Mercurius Health acquires Robert Janker Klinik in Bonn, Germany, previously owned by MEDICLIN

Retrieved on: 
Thursday, May 4, 2023
MVZ, Partnership, Clinic, Cancer, Diagnosis, Quality of life, Football Manager 2020, Brain, Research, Prostate, Radiation therapy, Mediclinic International, Radiation, Hospital, Interventional radiology, Acquisition, Patient, Palliative care, CFO, Medical imaging, Nursing

MediClin AG: Mercurius Health acquires Robert Janker Klinik in Bonn, Germany, previously owned by MEDICLIN

Key Points: 
  • MediClin AG: Mercurius Health acquires Robert Janker Klinik in Bonn, Germany, previously owned by MEDICLIN
    The issuer is solely responsible for the content of this announcement.
  • Mercurius Health acquires Robert Janker Klinik in Bonn, Germany, previously owned by MEDICLIN
    Robert Janker Klinik is specialised in radiotherapy, interventional radiology and palliative care.
  • The transaction includes the replacement of all equipment in the clinic to deliver state-of-the-art diagnostics and oncology related treatments.
  • MEDICLIN has found the right partner in Mercurius Health for the further development of the clinic, which specialises in minimally invasive diagnostics and cutting-edge oncology therapies.

Advancing Precision Care: GE HealthCare Introduces an Innovative Solution to Help Expand Interventional CT Access

Retrieved on: 
Tuesday, April 18, 2023
Oncology, Health, Neurology, Health Technology, Radiology, Biotechnology, IGT, GE HealthCare, Radiation, GPS, University, Therapy, Workflow, Drainage, Neoplasm, Anatomy, Molecular imaging, Learning curve, University of Pisa, GE, Needle, CT scan, Number One, MDR, Motion, Interventional radiology, Acquisition, European Conference on Information Retrieval, Patient, Division, European, Risk, Interventional oncology, Institut de radioprotection et de sûreté nucléaire, Diagnosis, FDA, Medical Device Regulation Act, Conference, Safety, Biopsy, Disease, Medical imaging, Medical device

Interventional radiology – and specifically interventional CT – plays a key role in the diagnosis and treatment of disease.

Key Points: 
  • Interventional radiology – and specifically interventional CT – plays a key role in the diagnosis and treatment of disease.
  • Instead of working wholly within the CT system’s narrow bore, interventionalists using CT-Navigation can simply place a sensor on the patient inside the gantry.
  • Today, the innovative solution focuses solely on CT applications, but GE HealthCare plans to expand the technology to its image guided therapy (IGT) business in the near future – further advancing its clinical application and reach.
  • Additionally, GE HealthCare is showcasing CT-Navigation at the European Conference on Interventional Oncology (ECIO) in Stockholm, Sweden.

"Vesteck, Inc. Successfully Completes Five Clinical Cases"

Retrieved on: 
Thursday, April 6, 2023
Interventional radiology, Surgeon, Workflow, Aorta, Coronavirus Scientific Advisory Board, Aneurysm, Patient, Physician, EVAR, Medical device

WEST CHESTER, Pa., April 6, 2023 /PRNewswire/ -- VESTECK, Inc. is pleased to announce the successful completion of 2 additional clinical cases with the "SUTURE-TIGHT" TM device.

Key Points: 
  • WEST CHESTER, Pa., April 6, 2023 /PRNewswire/ -- VESTECK, Inc. is pleased to announce the successful completion of 2 additional clinical cases with the "SUTURE-TIGHT" TM device.
  • Dr. Venkatesh Ramaiah, is the Chief and Network Director of Complex Vascular Services at Honor Health, Phoenix AZ.
  • For over 15 years, Dr. Ramaiah was the Chief of Vascular surgery at the famous AZ Heart Hospital.
  • "In 14 months, COO Kent Stalker, CTO Ted Wulfman and their engineering/R&D teams essentially created and brought this world class device to the clinical environment.

ProKidney Reports Fourth Quarter Financial Results and Recent Corporate Highlights

Retrieved on: 
Tuesday, March 28, 2023
Injection, Taiwan, Society, Kidney failure, Chronic kidney disease, D, Safety, PIPE, Society of Interventional Radiology, European Medicines Agency, REACT, SIR, Marketing, Interventional radiology, Journal, Patient, Physician, Kidney, Medicines and Healthcare products Regulatory Agency, Research, FDA, Health Canada, CKD, BLA, SVP, Food, SCS, Pharmaceutical industry, Cryptocurrency, EU

WINSTON-SALEM, N.C., March 28, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the fourth quarter ended December 31, 2022, and provided an update on recent corporate developments.

Key Points: 
  • WINSTON-SALEM, N.C., March 28, 2023 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced financial results for the fourth quarter ended December 31, 2022, and provided an update on recent corporate developments.
  • We remain actively engaged with the FDA, facilitated by REACT’s RMAT designation, to ensure that the steps we are taking today are positioning REACT for future success.
  • The Company currently has protocol allowances in Belgium, France, Singapore, Spain and Austria, with additional country-specific allowances pending.
  • Cash Position: Cash and cash equivalents as of December 31, 2022, were $490.3 million, compared to $20.6 million on December 31, 2021.

Gerry O’Sullivan, the Latest Member to Join Microbot Medical’s Scientific Advisory Board, to Leverage Extensive Interventional Radiology Experience to Progress the LIBERTY® Robotic System Through Regulatory, Clinical and Commercialization Phases

Retrieved on: 
Thursday, March 23, 2023
Well, Galway Clinic, SAB, IVC, KOL, Galway, Cardiovascular and Interventional Radiological Society of Europe, Society, Center of excellence, Intervention, Vision-guided robot systems, Consultant, Society of Interventional Radiology, Radiology, DVT, CIRSE, Prostate, Vein, SIR, Professor, Interventional radiology, Publication, Executive Committee, Clinical, SPC, European Board of Ophthalmology, Medical imaging

HINGHAM, Mass., March 23, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT) continues to receive global interest from interventional radiologists due to the gap in new innovative technology currently available on the market today. Microbot Medical, the company developing the LIBERTY® Robotic System, the first single-use endovascular robotic system, today announced that Professor Gerry O’Sullivan, a key opinion leader (KOL) from Ireland, has joined the Company’s Scientific Advisory Board (SAB). The Company believes the combination of his academic and medical experience will be invaluable while it seeks to establish Centers of Excellence throughout the U.S. and Europe in preparation for human clinical trials.

Key Points: 
  • Microbot Medical, the company developing the LIBERTY® Robotic System, the first single-use endovascular robotic system, today announced that Professor Gerry O’Sullivan, a key opinion leader (KOL) from Ireland, has joined the Company’s Scientific Advisory Board (SAB).
  • Annually, Professor O’Sullivan performs large volumes of prostate and uterine fibroid embolizations, as well as the full array of Interventional procedures.
  • “I believe interventional radiologists have been seeking a better solution to address their concerns, while still achieving favorable patient outcomes.
  • For a complete list and background on the members of the SAB, please visit the Company’s website at www.microbotmedical.com .

NRMP® Celebrates Match Day by Publishing the Results of a Record-Breaking 2023 Main Residency Match®

Retrieved on: 
Friday, March 17, 2023
Acceptance, Emergency medicine, Pediatrics, Obstetrics, Anesthesiology, Face, Obstetrics and gynaecology, Radiology, MBA, History, Competition (economics), BSN, Family medicine, Cardiothoracic surgery, Child, DO, National Resident Matching Program, Interventional radiology, NRMP, MD, Patient, Physician, Pathology, Doctor of Health Science, Internal medicine, Vascular surgery, Physical medicine and rehabilitation, Otorhinolaryngology, Neurology, IMG, Anne Ferguson-Smith, Internship, Integration, Orthopedic surgery, Developmental Medicine & Child Neurology, Nursing, Health insurance, Dentistry, SOAP, Psychiatry, Match, Gynaecology, Surgery

WASHINGTON, March 17, 2023 /PRNewswire/ -- The National Resident Matching Program® (NRMP®) celebrates the landmark milestone that is "Match Day" for the 2023 Main Residency Match with residency applicants, training programs, medical schools, and the medical education community.

Key Points: 
  • WASHINGTON, March 17, 2023 /PRNewswire/ -- The National Resident Matching Program® (NRMP®) celebrates the landmark milestone that is "Match Day" for the 2023 Main Residency Match with residency applicants, training programs, medical schools, and the medical education community.
  • "The 2023 Main Residency Match proved once again to be a highly successful Match with outstanding results for participants.
  • There were 48,156 total applicants registered in the 2023 Main Residency Match, an increase of 481 applicants over last year.
  • SOAP results will be available in the 2023 Main Residency Match Results and Data Book, which is published in the Spring.